RT期刊文章SR电子T1规范数据为多个呼吸冲刷的结果在学龄白人孩子摩根富林明欧洲呼吸杂志乔和J FD欧元欧洲呼吸学会SP 1901302 10.1183/13993003.01302 -2019 A1 Anagnostopoulou, Pinelopi A1 Latzin,菲利普A1詹森,蕾妮A1斯塔尔,Mirjam A1哈珀,188bet官网地址Alana A1 Yammine, Sophie A1 useman, Jakob A1 Foong, Rachel E. A1 Spycher, Ben A1 Hall, Graham L. A1 Singer, Florian A1 Stanojevic, Sanja A1 Mall, Marcus A1 Ratjen, Felix A1 Ramsey，氮多重呼吸洗脱(N2MBW)技术越来越多地被用于评估学龄期肺部疾病儿童的通气不均匀程度。但是，目前还没有健康儿童的参考值。本研究的目的是为一组健康高加索学龄儿童的N2MBW结果提供参考价值。方法收集4个有经验中心6 ~ 18岁健康白种人学龄儿童的N2MBW数据。使用超声波流量计(Exhalyzer D, Eco Medics AG, Duernten, Switzerland)进行测量，并使用商业软件(Spiroware, 3.2.1, Eco Medics AG)进行分析。分别生成2.5% (LCI2.5%)和5% (LCI5%)时肺清除率的标准值和正常值上限、矩比(M1/M0和M2/M0)和功能剩余容量(FRC)的预测方程。结果对180名6 ~ 18岁的健康白人儿童进行了485项试验分析。虽然LCI随年龄增长而增加，但这一增长可以忽略不计(LCI2.5%为0.04单位/年)，因此为这个年龄组定义了固定的正常上限。LCI2.5%为7.91,LCI5%为5.73,M1/M0为1.75,M2/M0为6.15。 Height and weight were found to be independent predictors of FRC.Conclusion We report reference values for N2MBW outcomes measured on a commercially available ultrasonic flowmeter device (Exhalyzer D, Eco Medics AG, Duernten, Switzerland) in healthy school-aged children to allow accurate interpretation of ventilation distribution outcomes and FRC in children with lung disease.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Anagnostopoulou has nothing to disclose.Conflict of interest: Dr. Latzin reports personal fees from Gilead, personal fees from Novartis, personal fees from Polyphor, personal fees from Santhera, personal fees from Schwabe, personal fees from Vertex, personal fees from Vifor, personal fees from Zambon, grants from Vertex, outside the submitted work.Conflict of interest: R. Jensen has nothing to disclose.Conflict of interest: Dr. Stahl reports personal fees from Vertex Pharmaceuticals, outside the submitted work.Conflict of interest: Dr. Harper has nothing to disclose.Conflict of interest: Dr. Yammine has nothing to disclose.Conflict of interest: Dr. Usemann has nothing to disclose.Conflict of interest: Dr. Foong has nothing to disclose.Conflict of interest: Dr. Spycher has nothing to disclose.Conflict of interest: Dr. Hall reports grants from NHMRC, Australia and USA CF Foundation, and non-financial support from ndd, during the conduct of the study.Conflict of interest: Dr. Singer reports personal fees from Vertex, personal fees from Novartis, outside the submitted work.Conflict of interest: Dr. Stanojevic has nothing to disclose.Conflict of interest: Dr. Mall reports grants from German Federal Ministry of Education and Research , grants from Einstein Foundation Berlin, during the conduct of the study; personal fees from Boehringer Ingelheim, personal fees from Vertex Pharmaceuticals, outside the submitted work.Conflict of interest: Dr. Ratjen reports grants and personal fees from Vertex, personal fees from Novartis, personal fees from Bayer, personal fees from Roche, personal fees from Genetech, outside the submitted work.Conflict of interest: Dr. Ramsey has nothing to disclose.